CAN 2109
Alternative Names: CAN-2109Latest Information Update: 24 May 2024
At a glance
- Originator CanWell Pharma
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Apr 2024 Preclinical trials in Solid tumours in China (Intratumoural), prior to April 2024 (NCT06332430)
- 02 Apr 2024 CanWell Pharma plans a phase I trial for Solid tumors or Lymphoma (Last-stage disease, Metastatic disease, Inoperable/Unresectable) in China in May 2024 (Intratumoural, Injection) (NCT06332430)